I think the question of a PR is complicated. On one hand, the effect on the pps at the conference would be greater. On the other hand, they are presenting at the ASCGT next week on the melanoma trial and wouldn't it be nice to mention the numbers that are already mentioned in the abstract (obviously they couldn't go further due to ASCO rules)? Also, they are now a featured presenter at the Marcum investor conference which would be a great place to promote data. I guess we will see.
Market Data 
Markets 
AI
